Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.

ABSTRACT: Multigene expression signatures provide a molecular subdivision of early breast cancer associated with patient outcome. A gap remains in the validation of such signatures in clinical treatment groups of patients within population-based cohorts of unselected primary breast cancer representing contemporary disease stages and current treatments. A cohort of 3520 resectable breast cancers with RNA sequencing data included in the population-based SCAN-B initiative (ClinicalTrials.gov ID NCT02306096) were selected from a healthcare background population of 8587 patients diagnosed within the years 2010-2015. RNA profiles were classified according to 19 reported gene signatures including both gene expression subtypes (e.g. PAM50, IC10, CIT) and risk predictors (e.g. Oncotype DX, 70-gene, ROR). Cla

SUBMITTER: Vallon-Christersson J 

PROVIDER: S-EPMC6704148 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature